What's next in tech
Maxygen, the Redwood City biotech company that hired Lazard last October to help it explore "strategic options" about the same time it laid off 30 percent of its staff, Read More → 
Bruce Peacock resigned today from the board of directors after serving less than two years there, where he also chaired its audit committee and was deemed its "financial expert" Read More → 
Louis Lange, the chief executive of CV Therapeutics, agreed in effect to sell his entire stake in the company to Gilead Sciences as an "inducement" to that company to enter into Read More → 
Astellas Pharma is appealing directly to the stockholder of CV Therapeutics, offering to give them $16 a share, an offer it has unsuccessfully made twice before to CV's board, most recently Read More → 
CV Therapeutics, the Palo Alto maker of the chest-pain treatment drug, Ranexa, said Friday the company's board turned down an offer to buy it for $16 a share from Read More → 
The board of directors at CV Therapeutics decided to extend by a year the shareholders rights plan they have in place to fend off hostile takeovers. The plan, otherwise Read More → 
